NSE/MAXHEALTH (NSE/MAXHEALTH)

National Stock Exchange of India: NSE/MAXHEALTH · INR

₹852

+6.51 (+0.8%)· Recorded snapshot

Market cap	827.3B
Revenue (ttm)	87.1B
Net income (ttm)	14.6B
EPS (ttm)	₹14.9
P/E (trailing)	57.1x
P/E (forward)	42.6x
Dividend	₹2.00 (0.23%)
Volume	7,242,507
Beta	0.10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 87.1B
Net income (ttm): 14.6B
EPS (ttm): ₹14.9
P/E (trailing): 57.1x
P/E (forward): 42.6x
Market cap: 827.3B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E42.6

P25 n/aP50 n/aP75 n/a

Trailing P/E57.1

P25 n/aP50 n/aP75 n/a

ROE14.3

P25 n/aP50 n/aP75 n/a

ROIC11.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NSE/MAXHEALTH indicators

Market & fundamental data

Available fields

233

Groups with data

Currency

INR

Showing 233 of 233 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	INR
Country	India
Country code	IN
Earnings date	2026-10-30
Employees	15,114
Employees change	-4,386
Employees growth	-22.49%
Enterprise value	INR 855.4B
Exchange	National Stock Exchange of India
Financial currency	INR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	March
Founded	2001
In index	NIFTY50
Industry	Medical Care Facilities
Is primary listing	No
ISIN number	INE027H01010
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Market cap	INR 827.3B
Next earnings date	2026-10-30
Price	INR 851.50
Price currency	INR
Sector	Healthcare
SIC code	8062
Stock price date	2026-10-28
Symbol	nse/MAXHEALTH
Website	https://www.maxhealthcare.in

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	55.58x
Average P/E ratio (3Y)	81.62x
Average P/E ratio (5Y)	71.02x
Earnings yield	1.75%
EV/Earnings	58.72x
EV/EBIT	46.32x
EV/EBITDA	37.13x
EV/FCF	574.93x
EV/Sales	9.82x
FCF / EV yield	0.17%
FCF yield	0.18%
Forward P/E	42.64x
Graham number	193.17956
Graham upside	-77.31%
Industry forward P/E	41.27x
Industry P/E	63.78x
Lynch fair value	INR 374.88
Lynch upside	-55.97%
P/(FCF - SBC) ratio	823.53x
P/(OCF - SBC) ratio	52.2x
P/B ratio	7.7x
P/E ratio	57.11x
P/FCF ratio	556.03x
P/OCF ratio	50.65x
P/S ratio	9.5x
Price / tangible book value	17.46x
Price/EBITDA ratio	36.84x
Sector forward P/E	36.12x
Sector P/E	45.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.2%
EBITDA margin	25.78%
Effective tax rate	14.84%
FCF margin	1.78%
Gross margin	62.52%
Operating margin	21.2%
Pretax margin	19.64%
Profit margin	16.72%
Profit per employee	INR 963,961
Profitable quarters	24
Profitable years	5
Revenue per employee	INR 5.8M
ROA	6.93%
ROA (5Y)	6.63%
ROCE	11.96%
ROE	14.33%
ROE (5Y)	13.21%
ROIC	11.6%
ROIC (5Y)	12.27%
SBC / revenue	0.58%
Tax / revenue	2.92%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	27.01%
EPS growth (Q)	4.76%
EPS growth (QoQ)	-5.78%
EPS growth 3Y	7.4%
EPS growth 5Y	33.7%
EPS growth quarters	6
EPS growth years	2
FCF growth	-69.85%
FCF growth 3Y	-46.07%
Gross profit growth	16.49%
Gross profit growth (Q)	17.71%
Gross profit growth 3Y	22.46%
Gross profit growth 5Y	25.45%
Net income growth	26.96%
Net income growth (Q)	4.72%
Net income growth (QoQ)	-5.77%
Net income growth 3Y	7.56%
Net income growth 5Y	35.11%
Net income growth quarters	6
Net income growth years	2
OCF growth	13.59%
OCF growth 3Y	8.35%
OCF growth 5Y	69.18%
Operating income growth	12.91%
Operating income growth (Q)	11.47%
Operating income growth 3Y	19.51%
Operating income growth 5Y	31.43%
Revenue growth	15.96%
Revenue growth (Q)	16.7%
Revenue growth (QoQ)	10.42%
Revenue growth 3Y	22.15%
Revenue growth 5Y	21.81%
Revenue growth quarters	23
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	INR -14.8B
Depreciation and amortization	INR 4B
EBIT	INR 18.5B
EBITDA	INR 22.5B
EPS	INR 14.91
Financing cash flow	INR 592.7M
Free cash flow	INR 1.5B
Free cash flow minus SBC	INR 1B
Gross profit	INR 54.5B
Income taxes	INR 2.5B
Investing cash flow	INR -16.9B
Net borrowing	INR 4B
Net cash flow	INR 42.2M
Net income	INR 14.6B
Operating cash flow minus SBC	INR 15.8B
Operating income	INR 18.5B
Revenue	INR 87.1B
Stock-based compensation	INR 483.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	INR 110.43
Debt / EBITDA	1.51
Debt / equity	0.32
Debt / FCF	23.38
Interest coverage	7.99
Net cash (debt)	INR -28.1B
Net cash / market cap	-3.4%
Net debt / EBITDA	1.25
Net debt / equity	0.26
Net debt / FCF	18.9
Piotroski F-Score	6
Shareholders' equity	INR 107.5B
Tangible book value	INR 47.4B
Tangible book value per share	INR 48.70
Total cash	INR 6.7B
Total debt	INR 34.8B
WACC	4.83%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.52
Current ratio	0.89
Inventory turnover	28.55
Quick ratio	0.8
Working capital	INR -2.4B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.05%
Dividend growth	33.33%
Dividend growth years	0
Dividend payment date	2026-08-29
Dividend payment years	4
Dividend payout frequency	Annual
Dividend per share	INR 2.00
Dividend yield	0.23%
Ex-dividend date	2026-07-03
Last dividend	INR 2.00
Payout ratio	13.41%
Shareholder yield	0.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	INR 1,010.88
1D price change	0.77%
1M price change	-16.03%
1M total return	-16.03%
1W price change	2.59%
1W total return	2.59%
1Y price change	-28.23%
1Y return CAGR	-28.12%
1Y total return	-28.1%
20-day SMA	INR 871.72
200-day SMA	INR 1,015.65
3M price change	-23.6%
3M total return	-23.6%
3Y price change	51.03%
3Y return CAGR	14.91%
3Y total return	51.73%
50-day SMA	INR 959.68
50-day SMA vs 200-day SMA	50under200
52-week high	INR 1,194.40
52-week high date	2025-10-29
52-week low	INR 797.00
52-week low date	2026-10-22
5Y price change	151.29%
5Y return CAGR	20.39%
5Y total return	152.88%
6M price change	-15.68%
6M total return	-15.53%
All-time high	INR 1,314.30
All-time high date	2025-07-04
All-time low	INR 64.65
All-time low date	2020-06-02
Average true range (ATR)	INR 27.97
Average volume	3.9M
Beta (5Y)	0.1
Change from 52-week high	-28.71%
Change from 52-week low	6.84%
Change from all-time high	-35.21%
Change from all-time low	1,217.09%
Change from open	1.98%
Day's gap	-1.18%
Dollar volume	INR 6.2B
High price	INR 857.00
Low price	INR 823.20
Monthly RSI	43.04
Open price	INR 835.00
Position in 52-week range	83.73%
Previous close	INR 845.00
Price vs 150-day SMA	-15.77%
Price vs 20-day SMA	-2.32%
Price vs 200-day SMA	-16.16%
Price vs 50-day SMA	-11.27%
Relative volume	1.86
RSI	35.98
Sharpe ratio	-1.35
Sharpe ratio (3Y)	0.48
Sharpe ratio (5Y)	0.55
Sortino ratio	-1.61
Sortino ratio (3Y)	0.89
Sortino ratio (5Y)	1.01
Volume	7.2M
Weekly RSI	35.75
YTD price change	-18.52%
YTD total return	-18.38%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	699.1M
Shares change (QoQ)	-0.05%
Shares change (YoY)	-0.05%
Shares held by insiders	23.73%
Shares held by institutions	49.19%

Deeper analysis on NSE/MAXHEALTH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NSE/MAXHEALTH report

Is a complete NSE/MAXHEALTH research report available?

No complete published report is available for nse/MAXHEALTH (NSE/MAXHEALTH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NSE/MAXHEALTH (NSE/MAXHEALTH)

Price

Financial snapshot

Fair-value bridge

Latest news · NSE/MAXHEALTH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NSE/MAXHEALTH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NSE/MAXHEALTH

Frequently asked questions